摘要
目的讨论乳腺癌新辅助化疗(NAC)对雌激素受体(ER)、孕激素受体(PR)和C-erbB-2的影响及意义。方法对2006年1月～2009年1月收入笔者所在医院进行乳腺癌治疗的96例患者在知情同意情况下进行新辅助化疗,使用免疫组化S-P试剂盒检测化疗前后96例患者的ER、PR和C-erbB-2表达有无变化。结果接受新辅助化疗后,患者的ER、PR、C-erbB-2表达水平无统计学意义(P<0.05),发生变化的仅分别为13、18、16例。结论新辅助化疗对乳腺癌患者的ER、PR、C-erbB-2表达水平无明显影响。
Objective To study the influence of neoadjuvant chemotherapy on expression of ER, PR and C - erbB - 2. Methods The expressions of ER.PR and C - erbB - 2 of 96 patients with breast cancer were investigated by SP immunohistochemieal method before and after Neoadjuvant Chemotherapy,whom were treated by Neoadjuvant Chemotherapy from jan- uary 2006 to january 2009 in our hospital. Results The difference of ER, PR and C - erbB - 2 before and after neoadjuvant chemotherapy were insignificant （ P 〉 0. 05 ） Only changes are 13,18 and 16 cases. Conclusion Neoadjuvant chemotherapy could not reduce the expression of ER ,PR and C -erbB -2 significantly.
出处
《中国医学创新》
CAS
2011年第17期18-19,共2页
Medical Innovation of China
作者简介
通讯作者：邹力君
